Heterogeneity of the baseline risk within patient populations of clinical trials: a proposed evaluation algorithm

scientific article

Heterogeneity of the baseline risk within patient populations of clinical trials: a proposed evaluation algorithm is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1093/OXFORDJOURNALS.AJE.A009590
P698PubMed publication ID9850135

P50authorJohn IoannidisQ6251482
P2093author name stringLau J
P433issue11
P407language of work or nameEnglishQ1860
P921main subjectheterogeneityQ928498
P304page(s)1117-1126
P577publication date1998-12-01
P1433published inAmerican Journal of EpidemiologyQ4744243
P1476titleHeterogeneity of the baseline risk within patient populations of clinical trials: a proposed evaluation algorithm
P478volume148

Reverse relations

cites work (P2860)
Q33915049A compendium of genome-wide associations for cancer: critical synopsis and reappraisal
Q30585625A framework for developing, implementing, and evaluating clinical prediction models in an individual participant data meta-analysis
Q102220359A simple score derived from bone marrow immunophenotyping is important for prognostic evaluation in myelodysplastic syndromes
Q74499672An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase
Q42762871Antibiotics for acute sinusitis in general practice. Entry criteria were too dissimilar for studies to be combined for meta-analysis
Q24288920Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal
Q47789168Assessing the applicability of trial evidence to a target sample in the presence of heterogeneity of treatment effect
Q93056000Charting the Path Forward for Risk Prediction in Liver Transplant for Hepatocellular Carcinoma: International Validation of HALTHCC Among 4,089 Patients
Q36710908Competing risk and heterogeneity of treatment effect in clinical trials
Q37253011Dealing with heterogeneity of treatment effects: is the literature up to the challenge?
Q51769291Digoxin Benefit Varies by Risk of Heart Failure Hospitalization: Applying the Tufts MC HF Risk Model
Q73536395Early mortality and morbidity of bilateral versus single internal thoracic artery revascularization: propensity and risk modeling
Q40373799Experimental designs for multicomponent interventions among persons with multifactorial geriatric syndromes.
Q34509675From concepts, theory, and evidence of heterogeneity of treatment effects to methodological approaches: a primer
Q59167772Haemoglobin targets: we were wrong, time to move on
Q64067632Heterogeneity of treatment effect by baseline risk of mortality in critically ill patients: re-analysis of three recent sepsis and ARDS randomised controlled trials
Q35198491Hypothermia in the management of traumatic brain injury. A systematic review and meta-analysis
Q37329334Interpretation of tests of heterogeneity and bias in meta-analysis
Q40219317Molecular evidence-based medicine: evolution and integration of information in the genomic era.
Q40689809Patterns of patient enrollment in randomized controlled trials
Q30635282Predictive modeling and heterogeneity of baseline risk in meta-analysis of individual patient data
Q44473667Race and Sex Differences in Response to Endothelin Receptor Antagonists for Pulmonary Arterial Hypertension
Q77839510Relationship between event rates and treatment effects in clinical site differences within multicenter trials: an example from primary Pneumocystis carinii prophylaxis
Q31112168Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials
Q90725243Scoring System to Optimize Pioglitazone Therapy After Stroke Based on Fracture Risk
Q78195503Sjögren's syndrome: too many associations, too limited evidence. The enigmatic example of CNS involvement
Q34382549Subgroup analyses in randomized controlled trials: the need for risk stratification in kidney transplantation
Q37212186The relative merits of population-based and targeted prevention strategies
Q31143342Using group data to treat individuals: understanding heterogeneous treatment effects in the age of precision medicine and patient-centred evidence

Search more.